Los Angeles Capital Management & Equity Research Inc. raised its stake in Merck & Company, Inc. (NYSE:MRK) by 2.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,387,287 shares of the company’s stock after purchasing an additional 38,345 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned approximately 0.05% of Merck & Company, Inc. worth $88,911,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MRK. RB Capital Management LLC raised its stake in shares of Merck & Company, Inc. by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after buying an additional 23 shares in the last quarter. Baystate Wealth Management LLC raised its stake in shares of Merck & Company, Inc. by 0.4% in the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after buying an additional 27 shares in the last quarter. Bath Savings Trust Co raised its stake in shares of Merck & Company, Inc. by 0.5% in the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after buying an additional 28 shares in the last quarter. Camelot Portfolios LLC raised its stake in shares of Merck & Company, Inc. by 0.4% in the 1st quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock valued at $494,000 after buying an additional 33 shares in the last quarter. Finally, Stillwater Investment Management LLC raised its stake in shares of Merck & Company, Inc. by 0.8% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock valued at $296,000 after buying an additional 38 shares in the last quarter. 73.85% of the stock is owned by hedge funds and other institutional investors.

In other Merck & Company, Inc. news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.25% of the stock is owned by corporate insiders.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at $55.87 on Friday. The stock has a market cap of $150,579.64, a PE ratio of 14.21, a P/E/G ratio of 2.56 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. Merck & Company, Inc. has a 1 year low of $53.63 and a 1 year high of $66.80.

Merck & Company, Inc. (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The business had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & Company, Inc. had a net margin of 11.60% and a return on equity of 27.08%. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter last year, the company posted $1.07 EPS. analysts expect that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 8th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.48 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $1.92 dividend on an annualized basis and a yield of 3.44%. This is a positive change from Merck & Company, Inc.’s previous quarterly dividend of $0.47. Merck & Company, Inc.’s dividend payout ratio is currently 112.58%.

A number of equities analysts have recently issued reports on MRK shares. Jefferies Group restated a “sell” rating and issued a $52.00 price objective on shares of Merck & Company, Inc. in a research note on Sunday, August 20th. BMO Capital Markets restated a “buy” rating and issued a $72.00 price objective on shares of Merck & Company, Inc. in a research note on Friday, September 8th. Credit Suisse Group dropped their price objective on shares of Merck & Company, Inc. from $75.00 to $74.00 and set an “outperform” rating for the company in a research note on Wednesday, August 30th. Sanford C. Bernstein restated a “buy” rating and issued a $64.00 price objective on shares of Merck & Company, Inc. in a research note on Wednesday, November 15th. Finally, SunTrust Banks cut shares of Merck & Company, Inc. from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Merck & Company, Inc. presently has a consensus rating of “Hold” and a consensus price target of $66.29.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Raises Holdings in Merck & Company, Inc. (MRK)” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/12/02/los-angeles-capital-management-equity-research-inc-raises-holdings-in-merck-company-inc-mrk.html.

Merck & Company, Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Company, Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.